APLMHealthcare · Biotechnology

APLM Stock Forecast: Apollomics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$23

−2.75% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 11 Sept 2026 — in the weakest quartile.

Market cap

$67.6M

Ticker Nerd rank

16 / 100

Median analyst target

—

Analysts covering

Total return, dividends reinvested

−17.2%

+27.8%

YTD

+24.1%

+270.1%

From 52W high

−36.7%

From 52W low

+270.1%

$37

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

APLM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apollomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026

16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Momentum

Issuance

Accruals

Volatility

Revisions

Growth

Value

Quality

Size (79): Smaller than most of the companies we track.

Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APLM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APLM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
8 May 2024	HC Wainwright & Co.	Maintains	Buy	$5.00 → $2.00
1 Apr 2024	EF Hutton	Maintains	Buy	—
1 Apr 2024	HC Wainwright & Co.	Maintains	Buy	—
20 Nov 2023	HC Wainwright & Co.	Reiterates	Buy	—
3 Oct 2023	HC Wainwright & Co.	Maintains	Buy	—
23 Aug 2023	EF Hutton	Assumes	Buy	$25
5 June 2023	HC Wainwright & Co.	Reiterates	Buy	—
1 June 2023	HC Wainwright & Co.	Initiates	Buy	—
25 May 2023	EF Hutton	Assumes	Buy	$25
25 Apr 2023	EF Hutton	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APLM appears on the weeks it earns a place.

Performance

APLM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Apollomics, Inc. returned +270.1% against +17.5% for the S&P 500, dividends included.

APLM vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APLM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Apollomics, Inc. (APLM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: 7.7×
Price / book: −97.7×
EV / EBITDA: −5.3×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 431.9%
Net margin: −123.7%

Returns & dividend

Return on equity: −1305.4%
Return on assets: −57.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Apollomics, Inc. (APLM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Apollomics, Inc. has a market value of $67.6M and an enterprise value of $48.3M.
Shares outstanding: 2.1M.
forward P/E: −35.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Apollomics, Inc. employs 14 people.

market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

APLM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
APLMApollomics, Inc.	$67.6M	16
RNTXRein Therapeutics, Inc.	$67.1M	36
XBITXBiotech, Inc.	$66.8M	31
DWTXDogwood Therapeutics, Inc.	$65.9M	37
TENXTenax Therapeutics, Inc.	$69.6M	22
CSBRChampions Oncology, Inc.	$70.3M	28
KLRSKalaris Therapeutics, Inc.	$70.9M	19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Apollomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APLM news & analysis

Apollomics Announces $10 Million Private Placement Transaction

GlobeNewsWire · 11 Aug 2026neutral

Apollomics Inc. announced it has entered into definitive subscription agreements for a private placement with accredited investors, expecting aggregate gross proceeds of approximately $10.0 million. The transaction is expected to close on or about August 14, 2026, subject to customary closing conditions.

Why it matters — A $10 million private placement would provide Apollomics with additional capital to support its late-stage oncology drug development programs.

FAQ

Frequently asked questions about APLM stock

How does Ticker Nerd's model rank APLM?

As at 11 Sept 2026, Apollomics, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

What is the APLM stock forecast for 2030?

No analyst covering Apollomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APLM are extrapolating price history, which says nothing about the business.

How has APLM stock performed over the past year?

Apollomics, Inc. returned +270.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Apollomics, Inc. do?

Apollomics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies for cancer treatment.

What is the latest news on APLM?

The most recent item we track (GlobeNewsWire, 11 Aug 2026): "Apollomics Announces $10 Million Private Placement Transaction". Apollomics Inc. announced it has entered into definitive subscription agreements for a private placement with accredited investors, expecting aggregate gross proceeds of approximately $10.0 million. The transaction is expected to close on or about August 14, 2026, subject to customary closing conditions.

Company

About Apollomics, Inc.

Apollomics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies for cancer treatment. The company’s current pipeline centers on targeted medicines and immuno-oncology approaches designed to address molecular drivers of disease and support use alongside other treatment options. Its lead programs include vebreltinib, an oral c-Met inhibitor being studied in solid tumors with MET dysregulation, and APL-102, an oral multi-kinase inhibitor in early-stage cancer development. Apollomics also evaluates therapies for difficult-to-treat cancers such as non-small cell lung cancer and acute myeloid leukemia. Based in Foster City, California, Apollomics operates as a specialized biotechnology company within the broader oncology drug-development market, where it contributes experimental therapies aimed at precision medicine and unmet medical needs.

CEO Mr. Hung-Wen Chen · 14 employees · United States · https://www.apollomicsinc.com